Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 2018 (2018), Article ID 4646852, 11 pages
https://doi.org/10.1155/2018/4646852
Research Article

Asthma Control and Asthma Medication Use among Swedish Elite Endurance Athletes

Department of Public Health and Clinical Medicine, Division of Medicine, Umeå University, Östersund, Umeå, Sweden

Correspondence should be addressed to Nikolai Stenfors; es.umu@srofnets.ialokin

Received 6 December 2017; Accepted 19 February 2018; Published 18 March 2018

Academic Editor: David Halpin

Copyright © 2018 Hampus Persson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Asthma is common in elite athletes. In this study, we examined the use of asthma medication and asthma control in endurance athletes in Sweden and compared the findings with those in a reference group of patients with asthma. Methods. The Asthma Control Test (ACT) and a questionnaire on asthma, respiratory symptoms, and medication use were posted to endurance athletes and the reference group of patients with asthma . Four hundred and sixty-nine athletes (66%) responded, of whom 141 (20%) reported physician-diagnosed asthma. In the reference group, 397 (39%) responded. Results. Seventy-seven percent of the athletes with asthma reported using asthma medication during the previous year; 39% used short/long-acting β2-agonists, 31% used inhaled corticosteroids, and 31% used both daily. According to the ACT scores, 19%, 24%, and 58% of athletes with asthma had uncontrolled, partially controlled, or well-controlled asthma, respectively. After adjustment, there was no difference in ACT scores or daily use of asthma medication between the study groups. Conclusions. Many endurance athletes had uncontrolled or partially controlled asthma, and one-third used inhaled corticosteroids and long-acting β2-agonists daily. Their adjusted ACT scores and use of asthma medication were similar to the values in the reference population.